Drug Approval | November 16, 2023
Imfinzi plus chemotherapy approved in China as for metastatic biliary tract cancer
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
Seamless transition from preclinical to first-in-human trials with EUDRACAP platform technology
The company has received six final approvals that includes Chlorpromazine Hydrochloride Tablets
Lupin has been exclusively marketing these brands in the Indian market since July 2021
Appointment further strengthens company’s expertise in fastest-growing therapeutic area to meet patient need
Parecoxib Sodium is the first parenteral selective COX-2 inhibitor available for clinical use in pain management
Mage Biologics to develop a monoclonal antibody targeting ulcerative colitis
Long COVID is a debilitating chronic condition that has affected over 100 million people globally
Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program
Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
Subscribe To Our Newsletter & Stay Updated
